Skip to main content
SpringerLink
Log in

Afatinib best value for money as first-line treatment for EGFR-mutated non-small-cell lung cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kim Y-J, et al. Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada. PharmacoEconomics : 31 Mar 2021. Available from: URL: https://doi.org/10.1007/s40273-021-01022-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib best value for money as first-line treatment for EGFR-mutated non-small-cell lung cancer. PharmacoEcon Outcomes News 876, 4 (2021). https://doi.org/10.1007/s40274-021-7618-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7618-y

Search

Navigation